Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Assets (2021 - 2026)

Axsome Therapeutics' Assets history spans 6 years, with the latest figure at $713.6 million for Q1 2026.

  • On a quarterly basis, Assets rose 19.6% to $713.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $713.6 million, a 19.6% increase, with the full-year FY2025 number at $689.8 million, up 21.34% from a year prior.
  • Assets hit $713.6 million in Q1 2026 for Axsome Therapeutics, up from $689.8 million in the prior quarter.
  • Over the last five years, Assets for AXSM hit a ceiling of $713.6 million in Q1 2026 and a floor of $88.6 million in Q1 2022.
  • Historically, Assets has averaged $509.6 million across 5 years, with a median of $568.5 million in 2024.
  • Biggest five-year swings in Assets: skyrocketed 339.45% in 2023 and later fell 10.37% in 2024.
  • Tracing AXSM's Assets over 5 years: stood at $331.5 million in 2022, then soared by 77.46% to $588.2 million in 2023, then decreased by 3.36% to $568.5 million in 2024, then grew by 21.34% to $689.8 million in 2025, then increased by 3.45% to $713.6 million in 2026.
  • Business Quant data shows Assets for AXSM at $713.6 million in Q1 2026, $689.8 million in Q4 2025, and $669.2 million in Q3 2025.